Overview

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.
Phase:
Phase 3
Details
Lead Sponsor:
Alvogen Korea
Treatments:
Candesartan
Candesartan cilexetil
Rosuvastatin Calcium